Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.780
-0.080 (-1.65%)
At close: Jun 12, 2026, 4:00 PM EDT
4.750
-0.030 (-0.63%)
Pre-market: Jun 15, 2026, 8:24 AM EDT
Aptevo Therapeutics Employees
Aptevo Therapeutics had 33 employees as of December 31, 2025. The number of employees decreased by 4 or -10.81% compared to the previous year.
Employees
33
Change (1Y)
-4
Growth (1Y)
-10.81%
Revenue / Employee
n/a
Profits / Employee
-$792,697
Market Cap
5.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 33 | -4 | -10.81% |
| Dec 31, 2024 | 37 | -3 | -7.50% |
| Dec 31, 2023 | 40 | -5 | -11.11% |
| Dec 31, 2022 | 45 | -9 | -16.67% |
| Dec 31, 2021 | 54 | -4 | -6.90% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| Cardio Diagnostics Holdings | 17 |
| Processa Pharmaceuticals | 12 |
| TransCode Therapeutics | 12 |
| XTL Biopharmaceuticals | 10 |
| Enveric Biosciences | 6 |
| Can-Fite BioPharma | 5 |
| Mustang Bio | 4 |
APVO News
- 18 days ago - Aptevo Therapeutics appoints Janatpour as SVP, CSO - TheFly
- 18 days ago - Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D. - Accesswire
- 18 days ago - Aptevo, Niowave launch collab for radiopharmaceutical oncology programs - TheFly
- 19 days ago - Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Accesswire
- 4 weeks ago - Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M - TheFly
- 4 weeks ago - Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire
- 5 weeks ago - Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial - TheFly
- 5 weeks ago - Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - Accesswire